Therefore, we performed several combination tests together with the KRASG12C inhibitor ARS-1620 suggested by either genome-scale CRISPR interference (CRISPRi) studies, which identified essential genes when KRAS as a tumor driver is inhibited [28] or by described resistance mechanisms as responses to KRASG12C inhibition [29,30]. This evidence concerns the gene KRAS and neoplasm.